A5006460186- HER2/EGFR in Cancer Research
- Breast Cancer Treatment Studies
- Cancer Treatment and Pharmacology
- Estrogen and related hormone effects
- Advanced Breast Cancer Therapies
- Cancer Cells and Metastasis
- Bone health and treatments
- Bone health and osteoporosis research
- Monoclonal and Polyclonal Antibodies Research
- Global Cancer Incidence and Screening
- BRCA gene mutations in cancer
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Immune Cell Function and Interaction
- Vitamin D Research Studies
- PARP inhibition in cancer therapy
- Cancer-related Molecular Pathways
- Lung Cancer Treatments and Mutations
- Immunotherapy and Immune Responses
- Radiomics and Machine Learning in Medical Imaging
- NF-κB Signaling Pathways
- CAR-T cell therapy research
- AI in cancer detection
- Radiopharmaceutical Chemistry and Applications
- DNA Repair Mechanisms
Hospital Del Mar
2016-2025
Hospital del Mar Research Institute
2013-2024
GEICAM – Spanish Breast Cancer Group
2016-2024
Centro de Investigación Biomédica en Red de Cáncer
2010-2024
Municipal Institute for Medical Research
2013-2023
Instituto de Salud Carlos III
2012-2021
Parc de Salut
2010-2018
Hospital Son Llatzer
2017
Hospital Virgen de la Salud
2017
Hospital Clínic de Barcelona
2016
We investigated the value of tumor-infiltrating NK (TI-NK) cells and HLA class I tumor expression as biomarkers response to neoadjuvant anti-HER2 antibody-based treatment in breast cancer.TI-NK HLA-I were determined by IHC pretreatment biopsies from two cohorts patients with HER2-positive cancer [discovery cohort (n = 42) validation 71)]. Tumor-infiltrating lymphocytes (TIL) scored according international guidelines. Biomarker association pathologic complete (pCR) disease-free survival (DFS)...
Abstract Background The variability in responses to neoadjuvant treatment with anti-HER2 antibodies prompts personalized clinical management and the development of innovative strategies. Tumor-infiltrating Natural Killer (TI-NK) cells can predict efficacy HER2-targeted independently from clinicopathological factors primary HER2-positive breast cancer patients. Understanding mechanism/s underlying this association would contribute optimizing patient stratification provide rationale for...
Purpose: Trastuzumab-emtansine (T-DM1) is a standard treatment in advanced HER2-positive breast cancer. However, resistance inevitably occurs. We aimed to identify mechanisms of acquired T-DM1 resistance.Experimental Design: cancer cells (HCC1954, HCC1419, SKBR3, and BT474) were treated pulse-fashion with induce resistant phenotype. Cellular molecular effects parental versus compared. CDK1 kinase activity cyclin B1 expression assayed under various conditions. Genetic modifications up- or...
Benign breast disease increases the risk of cancer. This association has scarcely been evaluated in context cancer screening programs although it is a prevalent finding mammography screening. We assessed distinct categories benign and subsequent cancer, as well influence family history A retrospective cohort study was conducted 545,171 women aged 50-69 years biennially screened for Spain. The median follow-up 6.1 years. age-adjusted rate ratio (RR) with disease, histologically classified...
Breast cancer is the most common in women our country and it usually diagnosed early potentially curable stages. Nevertheless, around 20–30% of patients will relapse despite appropriate locoregional systemic therapies. A better knowledge this disease improving ability to select therapy for each patient with a recent diagnosis an stage breast cancer, minimizing unnecessary toxicities long-term efficacy.
Importance RAD51C and RAD51D are involved in DNA repair by homologous recombination. Germline pathogenic variants (PVs) these genes associated with an increased risk of ovarian breast cancer. Understanding the recombination deficiency (HRD) status tumors from patients germline PVs RAD51C/D could guide therapeutic decision-making improve survival. Objective To characterize clinical tumor characteristics PV carriers, including evaluation HRD status. Design, Setting, Participants This...
The aim of this study was to compare estimates adherence oral endocrine therapy (OET) based on real-world data (RWD) and clinical evaluation in people diagnosed with breast cancer the public healthcare system Catalonia (Spain). We conducted two retrospective cohort studies. Cohort 1 consisted women 2021 Sources RWD were pharmacy billing register, hospital discharge records, Catalan health division's central insurance registry. Nonadherence defined as below 80% first year treatment. Data for...
Mitogen-activated protein kinase (MAPK) phosphatase-1 (MKP-1) dephosphorylates mitogen-activated [extracellular signal-regulated (ERK), c-Jun NH(2)-terminal (JNK), and p38], mediates breast cancer chemoresistance, is repressible by doxorubicin in cells. We aimed to characterize effects on MKP-1 phospho-MAPKs human cancers further study the clinical relevance of expression this disease.Doxorubicin MKP-1, phospho-ERK1/2 (p-ERK1/2), phospho-JNK (p-JNK), phospho-p38 were assayed a panel cells...
ObjectiveBaseline bone health in postmenopausal women is poorly characterized prospective series of early breast cancer (EBC) patients candidates to aromatase inhibitor (AI) therapy. Our objective comprehensively evaluate a clinical cohort recruited prior adjuvant AI therapy, with the aim establishing potential impact on loss and fractures.MethodsFrom January 2006 April 2010, we consecutively included 343 EBC who were about start Participants assessed at baseline (before initiation) 3...
// Alba Dalmases 1,2 , Irene González Silvia Menendez Oriol Arpí Josep Maria Corominas 3 Sonia Servitja Ignasi Tusquets 1,2,4 Cristina Chamizo 5 Raúl Rincón Lluis Espinosa 1 Anna Bigas Pilar Eroles 6 Jessica Furriol Lluch 7,8 Ana Rovira Joan Albanell 1,2,9 Federico Rojo 1,5 Cancer Research Program, IMIM (Hospital del Mar Institute), Barcelona, Spain; 2 Medical Oncology Department, Hospital Mar, Pathology 4 Autonomous University of IIS-Fundación Jiménez Díaz, Madrid, Institute Health INCLIVA,...
Patients' psychological reactions to multigene cancer panel testing might differ compared with the single-gene because of complexity and uncertainty associated different possible results. Understanding patients' preferences impact is important adapt genetic counselling model.One hundred eighty-seven unrelated patients clinical suspicion hereditary undergoing a 25-gene test completed questionnaires after pretest at 1 week, 3 months, 12 months results elicit their regarding disclosure measure...
Natural killer (NK) cells can orchestrate effective antitumor immunity. The presence of tumor-infiltrating NK in diagnostic biopsies predicts pathologic complete response (pCR) to HER2-specific therapeutic antibodies patients with primary breast cancer. Here, we analyzed whether diversity circulating might influence tumor infiltration and antibody efficacy. We found that numbers CD57+ inversely correlated pCR treatment cancer independently age, traditional clinicopathologic factors, CD16A...
The PEARL study showed that palbociclib plus endocrine therapy (palbociclib/ET) was not superior to capecitabine in improving progression-free survival postmenopausal patients with metastatic breast cancer resistant aromatase inhibitors, but better tolerated. This analysis compared patient-reported outcomes.The quality of life (QoL) population comprised 537 patients, 268 randomised palbociclib/ET (exemestane or fulvestrant) and 269 capecitabine. Patients completed the European Organisation...